




RealRate

PHARMACEUTICAL 2025

Serina Therapeutics Inc
Rank 186 of 225



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Serina Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Serina Therapeutics Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Serina Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 116%, being 99% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	5,676
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,366
Liabilities, Non-Current	268
Other Assets	547
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3,582
Other Net Income	5,841
Other Revenues	56
Property and Equipment	501
Research and Development	7,480
Selling, General and Administrative Expense	9,624

Output Variable	Value in 1000 USD
Assets	6,724
Liabilities	6,216
Expenses	17,104
Revenues	56
Stockholders Equity	508
Net Income	-11,207
Comprehensive Net Income	-11,207
BaseVar	17,970
ECR before Limited Liability	-156%
Economic Capital Ratio	116%